Are Two Antidepressants a Good Initial Treatment for Depression?
NCT00296712 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 55
Last updated 2012-04-27
Summary
Relatively drug naive patients will receive two antidepressant medications as initial treatment.
Conditions
- Major Depression
- Dysthymia
- Depression NOS
Interventions
- DRUG
-
escitalopram + bupropion
same dosing as for monotherapy arms
Sponsors & Collaborators
-
New York State Psychiatric Institute
lead OTHER
Principal Investigators
-
Jonathan W. Stewart, MD. · New York State Psychiatric Institute - Columbia University Department of Psychiatry
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-02-28
- Primary Completion
- 2006-07-31
- Completion
- 2006-07-31
Countries
- United States
Study Locations
More Related Trials
-
Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder
NCT02191397 ·Status: COMPLETED ·Phase: PHASE3
-
Add-on to Cognitive, Event-Related Potentials (ERP) and Electroencephalogram (EEG) Asymmetry in Affective Disorders
NCT03278938 ·Status: WITHDRAWN ·Phase: PHASE4
-
Effects of Antidepressants on Sexual Functioning
NCT00051259 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder
NCT00109044 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Depression in Adults
NCT00073697 ·Status: COMPLETED ·Phase: PHASE4
-
Escitalopram in Adult Patients With Major Depressive Disorder
NCT00668525 ·Status: COMPLETED ·Phase: PHASE3
-
Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder
NCT01541475 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder
NCT01148472 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder
NCT00432614 ·Status: COMPLETED ·Phase: PHASE3
-
Escitalopram as a Mood Stabilizer for Bipolar II Disorder
NCT00156325 ·Status: COMPLETED ·Phase: PHASE2
-
Escitalopram in the Treatment of Dysthymic Disorder, Double Blind
NCT00220701 ·Status: COMPLETED ·Phase: PHASE4
-
An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression
NCT00070694 ·Status: COMPLETED ·Phase: PHASE2
-
An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder
NCT00358631 ·Status: COMPLETED ·Phase: PHASE2
-
Dichotic Listening as a Predictor of Medication Response in Depression
NCT00404755 ·Status: COMPLETED ·Phase: PHASE4
-
SSRI and Buprenorphine
NCT00475878 ·Status: COMPLETED ·Phase: PHASE3
-
An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients
NCT00822744 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Escitalopram in Adult Patients With Major Depressive Disorder
NCT00108979 ·Status: COMPLETED ·Phase: PHASE3
-
Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder
NCT00239954 ·Status: UNKNOWN ·Phase: PHASE3
-
The Antidepressant Efficacy of the Anticholinergic Scopolamine
NCT00369915 ·Status: TERMINATED ·Phase: PHASE2
-
Neurobiological Bases of Placebo Response in Major Depressive Disorder
NCT01787240 ·Status: TERMINATED ·Phase: PHASE4
-
Developing New Clinical Management Strategies
NCT02082392 ·Status: COMPLETED ·Phase: PHASE4
-
Psilocybin and Depression
NCT03380442 ·Status: UNKNOWN ·Phase: PHASE2
-
Augmenting Antidepressant Treatment With Interpersonal Psychotherapy for Treating Late-life Depression
NCT00177294 ·Status: COMPLETED ·Phase: PHASE4
-
The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder
NCT00107120 ·Status: COMPLETED ·Phase: PHASE3
-
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
NCT05603104 ·Status: RECRUITING ·Phase: PHASE3